Barclays
INDV icon

Barclays’s Indivior Pharmaceuticals INDV Stock Holding History

Barclays’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37.2M Sell
907,024
-838,727
-48% -$30.4M 0.01% 859
2026
Q1 		$53.2M Sell
1,745,751
-132,406
-7% -$4.37M 0.01% 707
2025
Q4 		$67.4M Sell
1,878,157
-246,396
-12% -$7.52M 0.02% 642
2025
Q3 		$51.2M Buy
2,124,553
+25,493
+1% +$533K 0.01% 755
2025
Q2 		$30.9M Buy
2,099,060
+756,579
+56% +$8.81M 0.01% 907
2025
Q1 		$12.8M Buy
1,342,481
+570,101
+74% +$5.99M ﹤0.01% 1254
2024
Q4 		$9.6M Sell
772,380
-1,358,522
-64% -$14M ﹤0.01% 1604
2024
Q3 		$20.8M Sell
2,130,902
-2,559,245
-55% -$30M 0.01% 1050
2024
Q2 		$75.6M Buy
4,690,147
+2,611,175
+126% +$47.1M 0.02% 485
2024
Q1 		$44.5M Sell
2,078,972
-1,014,189
-33% -$19.1M 0.02% 662
2023
Q4 		$47.2M Buy
3,093,161
+2,727,791
+747% +$48.4M 0.02% 697
2023
Q3 		$8.43M Sell
365,370
-81,343
-18% -$1.85M 0.01% 1066
2023
Q2 		$10.6M Buy
+446,713
New +$10.2M 0.01% 971

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Barclays's INDV Position: Q2 2026 in Review

Barclays reduced its Indivior Pharmaceuticals (INDV) stake by 48% in Q2 2026, selling an estimated $30.4M and leaving 907,024 shares worth $37.2M. The position accounts for 0.01% of the portfolio, ranked #859.

Barclays first reported a position in INDV in Q2 2023 and has held it in 13 quarters since. The position peaked at $75.6M in Q2 2024. 338 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Barclays held 907,024 shares of Indivior Pharmaceuticals worth $37.2M as of Q2 2026.
  • Barclays sold 838,727 Indivior Pharmaceuticals shares in Q2 2026, an estimated $30.4M.
  • Indivior Pharmaceuticals made up 0.01% of Barclays's portfolio in Q2 2026, its #859 holding.
  • Barclays first reported a position in Indivior Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
  • Barclays's Indivior Pharmaceuticals position peaked at $75.6M in Q2 2024.
  • 338 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.